Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus.

BACKGROUND There is strong evidence that Th1 cytokines are essential for disease in murine models of lupus. Interleukin-12 (IL-12) is essential for Th1 cell differentiation and induces interferon-gamma (IFN-gamma) production. Paradoxically, it has been suggested that an IL-12 defect drives the pathogenesis of lupus, although its precise role remains unclear. We investigated the role of IL-12 for lupus-like disease induced by pristane. IL-12p35-deficient (-/-) and control (+/+) BALB/c mice were treated with pristane or phosphate-buffered saline (PBS). METHODS Proteinuria was measured and renal pathology evaluated 10 months after treatment. Sera were analyzed for autoantibodies and total immunoglobulin levels. Cytokine expression and production was analyzed. RESULTS Pristane induced nephritogenic autoantibodies and renal immunoglobulin and complement deposition in both IL-12 -/- and +/+ mice. However, proliferative pathology and proteinuria were absent in IL-12-/- mice, whereas pristane induced severe nephritis in one third of the +/+ mice. As expected, cytokine balance was skewed toward a Th2 response in pristane-treated IL-12 -/- mice. CONCLUSION These data indicate that renal immune complex deposition can occur in the absence of IL-12p35, but that structural renal damage requires the presence of IL-12p35 or mediators induced by this molecule, such as IFN-gamma. In contrast to the abrogation of nephritogenic autoantibodies by the lack of IFN-gamma, such antibodies are induced by pristane in IL-12p35-deficient mice. Absence of structural renal disease, despite the presence of nephritogenic autoantibodies in pristane-treated IL-12-/- mice, indicates that antibody deposition alone is not sufficient for the development of lupus nephritis in this model.

[1]  E. Shevach,et al.  Regulation of Interleukin (Il)-18 Receptor α Chain Expression on Cd4+ T Cells during T Helper (Th)1/Th2 Differentiation , 2001, The Journal of experimental medicine.

[2]  W. Egner The use of laboratory tests in the diagnosis of SLE , 2000, Journal of clinical pathology.

[3]  H. Weiner,et al.  IL-12 Drives IFN-γ-Dependent Autoimmune Kidney Disease in MRL-Fas lpr Mice , 1999, The Journal of Immunology.

[4]  T. Horiuchi,et al.  Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[5]  P. Woo,et al.  Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[6]  Y. Takasaki,et al.  Levels of IL‐12 in the sera of patients with systemic lupus erythematosus (SLE)—relation to Th1‐ and Th2‐derived cytokines , 1999, Clinical and experimental immunology.

[7]  D. Beller,et al.  Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. , 1998, Journal of immunology.

[8]  V. Poli,et al.  Interleukin 6 Dependence of Anti-DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristane-induced Lupus , 1998, The Journal of experimental medicine.

[9]  A. Schwarting,et al.  IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. , 1998, Journal of immunology.

[10]  H. Okamura,et al.  Regulation of interferon-γ production by IL-12 and IL-18 , 1998 .

[11]  G. Trinchieri,et al.  Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. , 1998, Arthritis and rheumatism.

[12]  B. Ryffel,et al.  IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. , 1998, Journal of immunology.

[13]  B. Ryffel,et al.  IFN-γ Receptor Deletion Prevents Autoantibody Production and Glomerulonephritis in Lupus-Prone (NZB × NZW)F1 Mice , 1998, The Journal of Immunology.

[14]  M. Satoh,et al.  Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. , 1998, Clinical immunology and immunopathology.

[15]  J. Ravetch,et al.  Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. , 1998, Science.

[16]  B. Croker,et al.  Functional dissection of systemic lupus erythematosus using congenic mouse strains. , 1997, Journal of immunology.

[17]  B. Ryffel,et al.  IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. , 1997, Journal of immunology.

[18]  J. Moslehi,et al.  Roles of interferon-gamma and interleukin-4 in murine lupus. , 1997, The Journal of clinical investigation.

[19]  Werner Müller,et al.  Interleukin-4 Protects against a Genetically Linked Lupus-like Autoimmune Syndrome , 1997, The Journal of experimental medicine.

[20]  D. Carvajal,et al.  IL‐12‐Deficient Mice Are Defective but Not Devoid of Type 1 Cytokine Responses , 1996, Annals of the New York Academy of Sciences.

[21]  G. Gilkeson,et al.  Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. , 1996, Arthritis and rheumatism.

[22]  S. Izui,et al.  Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. , 1996, The Journal of clinical investigation.

[23]  G. Feng,et al.  The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRLMP-lprlpr mice , 1996, The Journal of experimental medicine.

[24]  A. Kumar,et al.  Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Okamura,et al.  Cloning of a new cytokine that induces IFN-γ production by T cells , 1995, Nature.

[26]  B. Ryffel,et al.  Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon‐γ receptor inhibits the onset of glomerulonephritis , 1995, European journal of immunology.

[27]  G. Trinchieri,et al.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.

[28]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[29]  R. P. Wuthrich,et al.  Vascular cell adhesion molecule-1 (VCAM-1) expression in murine lupus nephritis. , 1992, Kidney international.

[30]  D. Wallace,et al.  Lupus erythematosus in the 1980s: a survey of 570 patients. , 1991, Seminars in arthritis and rheumatism.

[31]  E. Ginzler,et al.  Rheumatoid factor in patients with systemic lupus erythematosus. , 1989, The Journal of rheumatology.

[32]  A. Kohno,et al.  Genetic studies of autoimmunity in New Zealand mice. III. Associations among anti-DNA antibodies, NTA, and renal disease in (NZB x NZW)F1 x NZW backcross mice. , 1981, Journal of immunology.

[33]  P. Schur,et al.  Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). , 1981, Medicine.

[34]  A. Grayzel,et al.  The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis: a two year prospective study. , 1978, The American journal of medicine.

[35]  J. Hayslett,et al.  PROGNOSTIC INDICES IN LUPUS NEPHRITIS , 1976, Medicine.

[36]  P. Schur,et al.  IMMUNOLOGICAL STUDIES CONCERNING THE NEPHRITIS OF SYSTEMIC LUPUS ERYTHEMATOSUS , 1967, The Journal of experimental medicine.

[37]  H. Yoshida,et al.  Interferon- (cid:1) is required for lupus nephritis in mice treated with the hydrocarbon oil pristane , 2022 .

[38]  S. Y. Yang,et al.  Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. , 2001, Scandinavian journal of rheumatology.

[39]  B. Ryffel,et al.  Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. , 1997, The Journal of experimental medicine.

[40]  R. Wüthrich,et al.  Up-regulation of tubular epithelial interleukin-12 in autoimmune MRL-Fas(lpr) mice with renal injury. , 1997, Kidney international.

[41]  D. Carvajal,et al.  Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. , 1994, International immunology.